Endometrial adenocarcinoma and low-grade endometrial stromal sarcoma were rare in the present study and there were no reports of leiomyosarcoma.
To facilitate removal of extirpated tissue during minimally invasive surgery, the uterus or a myoma is cut into small pieces (morcellated), allowing the specimen to be removed through smaller incisions. The power morcellator is an electromechanically-assisted instrument with a rotating blade that cuts the specimen into fragments at the time of the procedure. Morcellation can be performed in either a contained environment using a retrieval bag (closed) or uncontained (open) within the abdominal cavity.
In November 2014, the FDA stipulated that power morcellation should not be used for "the majority of women" undergoing uterine fibroid surgery owing to the potential risk of spreading occult malignancy. 7 Based on a literature review, the statement concluded that, among women undergoing a hysterectomy or myomectomy for fibroids, the prevalence of uterine sarcoma and unsuspected uterine leiomyosarcoma were 1 in 352 and 1 in 498, respectively. 7 Following the FDA statement on power morcellation, Pritts et al. 8 performed a meta-analysis of 133 studies where surgery was performed for myomas and patient histopathology was known; the prevalence of leiomyosarcoma was approximately 1 in 2000 (0.05%) surgeries and was further reduced to 1 in 8300 surgeries when the analysis was restricted to 64 prospective studies. 8 From these two systematic reviews, the reported prevalence of leiomyosarcoma is within the range 1 in 498-8300 hysterectomies or myomectomies performed for myoma. Other concerns related to open power morcellation include that, if an undiagnosed uterine malignancy is present, accurate surgical staging is difficult and the lack of management and optimal treatment guidelines for these patients presents further challenges. 9 The objective of the present study was to quantify the prevalence of pre-malignant and malignant uterine pathology among women undergoing hysterectomy or myomectomy for benign disease with open power morcellation, and to describe long-term outcomes and management among these patients. It was hypothesized that a low prevalence of unexpected uterine pathology would be recorded at the time of surgical treatment for benign disease among women undergoing open power morcellation. 10 and were analyzed using SAS version 9.4 (SAS institute, Cary, NC, USA). patients had pre-malignant or malignant uterine pathology; of these patients, 6 (43%) had endometrial hyperplasia and 8 (57%) had occult uterine malignancy, corresponding to prevalence rates of 0.5% and 0.7% for pre-malignant pathology and malignant pathology, respectively. Preoperative characteristics of women with pre-malignant or malignant pathology were similar to those of patients with normal pathology, including body mass index, parity, hypertension, diabetes, breast cancer, and smoking (all P>0.129) ( Table 1) .
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Among the six patients with pre-malignant pathology, there were
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and leiomyomas. There were 4 (67%) patients with pre-malignant pathology who had a negative preoperative endometrial biopsy and 4 (67%) who had a pelvic ultrasonography examination that showed an endometrial stripe thinner than 5 mm.
Of the eight patients with occult uterine malignancy, 5 (63%) had endometrial adenocarcinoma, corresponding to an overall prevalence rate of 0.4% within the whole study cohort. Of these eight patients, 1 (13%) had a low-grade endometrial stromal sarcoma, 1 (13%) had a uterine tumor resembling an ovarian sex cord tumor, and 1 (13%) had atypical leiomyoma, equivalent to an overall prevalence of 0.1% for each, respectively (Table 2 ). There were no occurrences of leiomyosarcoma in the study cohort and endometrioid adenocarcinoma of the ovary was identified in one patient; the ovary was not morcellated and the patient underwent repeat surgical exploration and intraperitoneal chemotherapy.
Of the eight patients who were found to have an occult malig- T A B L E 2 Surgical pathology, subsequent surgery, and adjuvant therapy for patients with occult uterine malignancy (n=8 patients undergoing surgery for uterovaginal prolapse). There were 5 (63%) patients with occult malignancy aged younger than 50 years, 3 (38%) aged 51-60 years, and none older than 65 years ( Table 2 ).
All patients who were found to have malignant pathology un- The patient with a uterine tumor resembling an ovarian sex cord tumor underwent a second staging procedure with benign pathology.
The patient with a low-grade endometrial stromal sarcoma also underwent a second operative procedure and a low-grade endometrial stromal sarcoma of the right adnexa was found. In the patient who had an atypical leiomyoma, this was found to occur in a myomectomy specimen; a total abdominal hysterectomy was performed and benign uterine pathology was found. No further treatment was necessary for these patients (Table 2 ). Pre-malignant and malignant pathology were recorded in the present cohort, despite a benign preoperative endometrial biopsy and/or unremarkable pelvic ultrasound. The sensitivity of an endometrial biopsy to detect endometrial cancer is 94% with a specificity of 99%.
11
If pelvic ultrasonography demonstrates an endometrial stripe thicker than 5 mm, the sensitivity and specificity for detecting endometrial cancer are 55% and 97%, respectively. 11 These findings highlight the clinical predicament arising from imperfect sensitivity and specificity in the preoperative evaluation of women undergoing hysterectomy for presumed benign disease.
Einstein et al. 12 recommended that surgical exploration was repeated in all patients found to have a malignancy in the morcellated specimen. Of the eight patients with occult uterine malignancy in the present cohort, 1 (13%) was surgically upstaged after the diagnosis of low-grade endometrial stromal sarcoma in the right adnexa. These findings were similar to those of Einstein et al. 12 who reported that 15% of patients were upstaged following repeat surgical exploration.
The present findings were also supported by a study by Bojahr et al.; 13 in their large population-based prospective registry study of 10 731 morcellated uteri during laparoscopic supracervical hysterectomy, seven of the eight patients with endometrial carcinoma (overall rate of 0.07%) underwent repeat surgery and no recurrences were reported over a mean follow-up time of 74 months. 13 In their study, there were six sarcomas (prevalence rate 0.06%) and all patients underwent repeat surgical exploration. including only being able to assess symptoms and findings documented in medical charts. Given its rarity, leiomyosarcoma was not detected in any patients and a larger sample size could have generated a more accurate assessment of the prevalence of this rare malignancy.
In the present large cohort of women undergoing open power morcellation for benign indications, pre-malignant and malignant uterine pathology were rare. Leiomyosarcoma was not detected in any patients and no potential risk factors for abnormal uterine pathology were identified. Given this, improved diagnostic methods are needed to help differentiate pre-malignant/malignant and benign uterine pathology. Further studies are needed to investigate and determine more accurate methods for preoperative evaluation prior to hysterectomy or myomectomy.
The power morcellator has reduced the morbidity associated with open surgery 14, 15 and this technique should not be abandoned altogether;
rather, efforts should continue to refine methods for mitigating risks, such as effective containment of specimens and enhancing the clinical diagnosis of pre-malignant and malignant uterine pathology. These refinements, in the setting of strict guidelines and clinical recommendations for the use of power morcellation, will allow the continuation of providing safe minimally invasive surgical approaches for patients.
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